<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02636283</url>
  </required_header>
  <id_info>
    <org_study_id>15SDG25360025</org_study_id>
    <nct_id>NCT02636283</nct_id>
  </id_info>
  <brief_title>Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease</brief_title>
  <official_title>Use of Entresto (Sacubitril/Valsartan) for the Treatment of Peripheral Arterial Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Heart Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study proposes the use of Entresto (sacubitril/valsartan) to test the effects on pain
      free walking duration on patients with peripheral arterial disease, a condition caused by
      decreased blood flow to the muscles in the legs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current approaches for the treatment of peripheral arterial disease (PAD) lack the success
      observed in the treatment of other forms of vascular diseases. A potential reason for this
      may be that available treatments do not target the pathological mechanisms implicated in the
      development of PAD. These mechanisms include obstruction of aortic-iliac arteries and its
      branches due to the formation of atherosclerotic plaques and mitochondrial and microvascular
      dysfunction. Although blood flow improves following surgical revascularization, pain free and
      maximal walking duration does not improve to the same degree. This suggests that in addition
      to blood flow obstruction, mitochondrial and microvascular dysfunction are significant
      factors implicated in the development of PAD.

      Therefore, any treatment designed for patients with PAD should be aimed at improving
      mitochondrial and microvascular function. In this regard, natriuretic peptides (NP) have been
      shown to increase mitochondrial and microvascular density and these two findings have been
      associated with increases in oxygen consumption and perfusion of skeletal muscles.

      The Investigator proposes that an increase in endogenous natriuretic peptides by inhibiting
      the enzyme that degrades it in blood will increase mitochondrial and microvascular function
      and this will be associated with an increase in maximal and pain free walking duration. To
      test this hypothesis the investigators have designed a double blind randomized controlled
      clinical trial providing sacubitril/valsartan for 12 weeks trial period.The improvements in
      mitochondrial and microvascular function will be measured using magnetic resonance (MR)
      spectroscopy and functional MR imaging and an exercise stress test will be used to assess
      maximal and pain free walking duration. This trial will provide patients with PAD with a
      non-surgical, cause-specific treatment option.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment
  </why_stopped>
  <start_date type="Actual">December 31, 2017</start_date>
  <completion_date type="Actual">November 1, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treadmill Walk Until Pain Initiated in Minutes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Time in minutes on a standardized treadmill test to initiation of pain and time until pain requires patient to stop walking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial and Microvascular Function Arterial Elasticity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Post-contraction measures of mitochondrial and microvascular function using MR spectroscopy and functional MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Using Homeostasis Model Assessment (HOMA) index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Elasticity</measure>
    <time_frame>12 weeks</time_frame>
    <description>Pulse wave pressure analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaires describing independent living and quality of life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Entresto</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral route</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entresto</intervention_name>
    <description>Oral pills</description>
    <arm_group_label>Entresto</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo group</intervention_name>
    <description>The placebo pills</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject with symptoms of intermittent claudication, such as exercise-induced pain,
             cramps, fatigue, or other equivalent discomfort, involving large muscle groups of the
             leg(s) (calf, thigh, buttocks), relieved by rest.

          2. Ankle-brachial index â‰¤ 0.90 acquired according to the American Heart Association
             guidelines.

          3. Highest ankle pressure reduced by at least 25 mm Hg after exercise compared to resting
             pressure (or loss of previously present Doppler signal for both the posterior tibial
             and anterior tibial arteries immediately after exercise if arteries were
             incompressible).

          4. Patients on medical treatment for PAD without significant improvement in intermittent
             claudication within the last 6 months.

        Exclusion Criteria:

          1. Age &lt; 18 and &gt; 80 years.

          2. Patients with physician diagnosed chronic kidney disease or heart failure stage II or
             IV or unstable angina.

          3. Echocardiographic evidence of cardiomyopathies and pulmonary hypertension.

          4. Patients that have received cancer treatment within the last year (except skin
             cancer).

          5. Severe limitations in mobility due to osteomuscular disorders present at time of
             interview.

          6. Dementia or other mental disorders that prevent patients from following a research
             protocol present at time of interview

          7. Patients engaged in an exercise rehabilitation program within the past 6 months.

          8. Patients schedule to undergo an arterial revascularization procedure during the study
             or have undergone one within the past 6 months.

          9. Inconsistent maximal walking distance on the treadmill test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Otto A Sanchez, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2015</study_first_posted>
  <results_first_submitted>December 5, 2019</results_first_submitted>
  <results_first_submitted_qc>December 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2019</results_first_posted>
  <last_update_submitted>December 5, 2019</last_update_submitted>
  <last_update_submitted_qc>December 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>LCZ 696</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 21, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/83/NCT02636283/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Entresto</title>
          <description>oral route
Entresto: Oral pills</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Oral placebo
Placebo group: The placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Terminated Prematurely</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entresto</title>
          <description>oral route
Entresto: Oral pills</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Oral placebo
Placebo group: The placebo pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.7" spread="4.16"/>
                    <measurement group_id="B2" value="62.7" spread="3.06"/>
                    <measurement group_id="B3" value="61.7" spread="3.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="00"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Treadmill Walk Until Pain Initiated in Minutes</title>
        <description>Time in minutes on a standardized treadmill test to initiation of pain and time until pain requires patient to stop walking</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated prematurely; outcome measure data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Entresto</title>
            <description>oral route
Entresto: Oral pills</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Oral placebo
Placebo group: The placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Treadmill Walk Until Pain Initiated in Minutes</title>
          <description>Time in minutes on a standardized treadmill test to initiation of pain and time until pain requires patient to stop walking</description>
          <population>Study terminated prematurely; outcome measure data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mitochondrial and Microvascular Function Arterial Elasticity</title>
        <description>Post-contraction measures of mitochondrial and microvascular function using MR spectroscopy and functional MRI</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated prematurely; outcome measure data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Entresto</title>
            <description>oral route
Entresto: Oral pills</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Oral placebo
Placebo group: The placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Mitochondrial and Microvascular Function Arterial Elasticity</title>
          <description>Post-contraction measures of mitochondrial and microvascular function using MR spectroscopy and functional MRI</description>
          <population>Study terminated prematurely; outcome measure data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>Using Homeostasis Model Assessment (HOMA) index</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated prematurely; outcome measure data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Entresto</title>
            <description>oral route
Entresto: Oral pills</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Oral placebo
Placebo group: The placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>Using Homeostasis Model Assessment (HOMA) index</description>
          <population>Study terminated prematurely; outcome measure data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Elasticity</title>
        <description>Pulse wave pressure analysis</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated prematurely; outcome measure data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Entresto</title>
            <description>oral route
Entresto: Oral pills</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Oral placebo
Placebo group: The placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Elasticity</title>
          <description>Pulse wave pressure analysis</description>
          <population>Study terminated prematurely; outcome measure data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Questionnaires</title>
        <description>Questionnaires describing independent living and quality of life</description>
        <time_frame>12 weeks</time_frame>
        <population>Study terminated prematurely; outcome measure data was not collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Entresto</title>
            <description>oral route
Entresto: Oral pills</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Oral placebo
Placebo group: The placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Questionnaires</title>
          <description>Questionnaires describing independent living and quality of life</description>
          <population>Study terminated prematurely; outcome measure data was not collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Entresto</title>
          <description>oral route
Entresto: Oral pills</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Oral placebo
Placebo group: The placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Pain during study procedure due to pre-existing condition</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Otto Sanchez</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>615-833-9867`</phone>
      <email>sanc0050@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

